Tenaya Therapeutics, Inc. (TNYA) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US87990A1060

Price

0.40 USD

Market cap

89.33 m USD

P/E (2026)

–

P/S (2026)

–

Dividend yield

0.00 %

Net margin

–

Return on equity (ROE)

–

Return on assets (ROA)

–

Tenaya Therapeutics, Inc. financials

Fiscal year	2025
Operating income	-93.33 m USD
EBIT	-93.28 m USD
Net income	-90.60 m USD
Diluted EPS – continuing operations	-0.59 USD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.